{"id":778880,"date":"2025-12-10T10:26:01","date_gmt":"2025-12-10T10:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=778880"},"modified":"2025-12-10T10:26:01","modified_gmt":"2025-12-10T10:26:01","slug":"drug-discovery-services-market-global-growth-outlook-key-drivers-and-competitive-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/drug-discovery-services-market-global-growth-outlook-key-drivers-and-competitive-landscape_778880.html","title":{"rendered":"Drug Discovery Services Market: Global Growth Outlook, Key Drivers, and Competitive Landscape"},"content":{"rendered":"
\n
\"Drug<\/a><\/div>\n
\n
The report profiles key players such as Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others.<\/div>\n<\/div>\n<\/div>\n
Browse 577 market data Tables and 64 Figures spread through 450 Pages and in-depth TOC on “Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User – Global Forecast to 2030<\/div>\n

The Drug Discovery Services Market<\/strong> is undergoing significant expansion as pharmaceutical and biopharmaceutical companies increase their investments in research and development. Valued at US$14.89 billion in 2024<\/strong>, the market is projected to grow at a robust CAGR of 10.7%<\/strong>, reaching US$16.36 billion in 2025<\/strong> and US$27.23 billion by 2030<\/strong>. This growth is driven by rising R&D activity, the high cost of internal drug development, increasing reliance on contract research organizations (CROs), and a continuous need for specialized analytical testing.<\/p>\n

As the global therapeutic pipeline expands—particularly in areas such as oncology, rare diseases, immunology, and neurology—companies are outsourcing more discovery activities to experienced service providers. These partners deliver advanced scientific capabilities, modern technologies, and cost-effective solutions that accelerate early-stage research and improve overall drug development success rates.<\/p>\n

Download PDF Brochure: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=138732129<\/a><\/strong><\/p>\n

Key Market Drivers<\/strong> 1. Rising R&D Expenditure Among Pharmaceutical and Biopharmaceutical Companies<\/strong><\/p>\n

Pharmaceutical and biotech firms continue to increase their investments in drug discovery to support expanding therapeutic pipelines. The development of biologics, gene therapies, cell therapies, and novel small molecules requires sophisticated R&D infrastructure, which many companies prefer to outsource to reduce timelines and costs.<\/p>\n

2. Outsourcing of Analytical and Specialized Testing<\/strong><\/p>\n

As discovery science becomes more complex, the need for high-end analytical testing<\/strong>, toxicology studies, high-throughput screening, and ADME\/PK services increases. Outsourcing these functions enables companies to access specialized expertise, standardized workflows, and advanced instrumentation—significantly improving the efficiency of drug discovery programs.<\/p>\n

3. Focus on Rare Diseases and Orphan Drug Research<\/strong><\/p>\n

The rising number of research initiatives targeting rare diseases and orphan drugs<\/strong> is creating additional demand for drug discovery services. Companies working in these niche areas often require customized assays, advanced modeling techniques, and expert-driven studies, making outsourcing an essential part of their strategy.<\/p>\n

4. High Cost and Complexity of In-House Drug Development<\/strong><\/p>\n

Building and maintaining internal drug discovery infrastructure—including laboratories, equipment, and scientific talent—is highly resource-intensive. Contract research organizations (CROs) offer a cost-effective alternative by providing ready access to multidisciplinary teams and cutting-edge technologies.<\/p>\n

5. Advancements in Drug Discovery Technologies<\/strong><\/p>\n

Modern technologies such as: • AI and machine learning–based drug design • Structure-based drug design • High-throughput screening • CRISPR gene editing • Combinatorial chemistry • In-silico and computational modeling<\/p>\n

are creating new opportunities for enhanced accuracy, faster timelines, and lower costs. As these technologies evolve, demand for specialized drug discovery services continues to rise across both small and large pharmaceutical companies.<\/p>\n

Market Segmentation by Service Type<\/strong><\/p>\n

The drug discovery services market is broadly categorized into chemistry services<\/strong> and biology services<\/strong>.<\/p>\n

Chemistry Services Dominated the Market in 2024<\/strong><\/p>\n

The chemistry services segment<\/strong> accounted for the largest market share in 2024 due to strong demand for: • Combinatorial chemistry • Medicinal chemistry • Analytical chemistry • Structure-based drug design • Fragment-based drug discovery<\/p>\n

These services are essential for identifying and optimizing lead molecules with favorable therapeutic profiles. As the need for safe, effective, and high-quality drugs increases globally, the chemistry segment is expected to continue leading the market.<\/p>\n

Biology Services Support Biologics and Advanced Therapies<\/strong><\/p>\n

Biology services—covering assays, cell-based studies, target validation, pharmacology, and bioinformatics—are becoming increasingly important as biologics gain traction. Biopharmaceutical companies are prioritizing biologic drug discovery due to: • High clinical success rates of biologics • Rising demand for targeted therapies • Growth of biosimilars • Increasing prevalence of chronic and autoimmune disorders<\/p>\n

Because biologics require specialized research capabilities and complex development workflows, companies are outsourcing more biology-focused services to experienced CROs.<\/p>\n

Market Segmentation by Drug Type: Biologics vs. Small Molecules<\/strong><\/p>\n

The drug type segment is divided into: • Biologics<\/strong> • Small molecules<\/strong><\/p>\n

Biologics Segment Showing Rapid Growth<\/strong><\/p>\n

Biologics—including monoclonal antibodies, recombinant proteins, and advanced modalities—continue to gain prominence due to their high specificity and therapeutic potential. Several factors are fueling growth in this segment: • Increased biopharma investments • Rising complexity of biologic drug development • High cost of biologics and the need for efficient discovery approaches • Growing demand for biosimilars to address patent expirations • Outsourcing of biologics R&D to CROs with specialized facilities<\/p>\n

The shift toward biologics is expected to reshape drug discovery workflows, making biology-focused services a critical market driver over the next decade.<\/p>\n

Regional Insights<\/strong><\/p>\n

The drug discovery services market is segmented into: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.<\/strong><\/p>\n

North America Leads the Global Market<\/strong><\/p>\n

North America dominated the market in 2024 due to: • A large base of established CROs • High R&D spending by pharmaceutical and biotech companies • Growing biosimilars and biologics development • Strong presence of big pharma and academic institutions • Widespread adoption of advanced discovery technologies<\/p>\n

The US remains a major hub for early-stage drug discovery, benefiting from a strong regulatory framework, skilled workforce, and cutting-edge research infrastructure.<\/p>\n

Asia Pacific is the Fastest-Growing Region<\/strong><\/p>\n

The Asia-Pacific (APAC) drug discovery services market<\/strong> is expanding rapidly due to: • Growth of pharmaceutical and biopharmaceutical manufacturing • Increasing number of CROs in China, India, and South Korea • Lower operational costs compared to Western markets • Favorable government policies promoting R&D • Less-stringent regulations for early-stage discovery processes<\/p>\n

APAC is emerging as a preferred outsourcing destination, particularly for chemistry, biology, and preclinical research services.<\/p>\n

Key Players in the Market<\/strong><\/p>\n

Prominent companies operating in the global drug discovery services market include: • Charles River Laboratories (US)<\/strong> • Thermo Fisher Scientific (US)<\/strong> • WuXi AppTec (China)<\/strong> • Pharmaron (China)<\/strong> • Labcorp (US)<\/strong> Other notable players contribute significantly through innovations in discovery platforms, AI-driven drug development, and biologics research.<\/p>\n

Conclusion<\/strong><\/p>\n

The Drug Discovery Services Market<\/strong> is poised for sustained growth driven by rising pharmaceutical R&D spending, increasing outsourcing trends, and strong advances in drug discovery technologies. Chemistry services remain the backbone of early discovery, while biologics research is gaining momentum due to its therapeutic advantages. With North America leading the market and Asia Pacific emerging as a fast-growing outsourcing hub, global CROs are well-positioned to meet the rising demand for efficient, cost-effective, and innovative drug discovery solutions through 2030.<\/p>\n

Request Sample Pages : <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=138732129<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Rohan Salgarkar
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City:<\/strong> Florida
State:<\/strong> Florida
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/drug-discovery-services-market-138732129.html<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

The report profiles key players such as Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others. Browse 577 market data Tables and 64 Figures spread through 450 Pages and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-778880","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/778880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=778880"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/778880\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=778880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=778880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=778880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}